mosunetuzumab

New Drug Elicits Positive Reaction for Treatment of Poor-Prognosis non-Hodgkin Lymphoma (NHL)

Per recent study, patients with B-cell NHL (non-Hodgkins Lymphoma) who failed to respond to prior treatment therapies show positive results when given mosunetuzumab, a new investigational drug. This new drug targets two proteins, one on the surface of tumor cells and the other on the surface of the recipient’s T cells. The study has been...

Categories

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.